Publicaciones - Leishmaniasis 

Valderrama C; Alexander N; Ferro C; Cadena H, Marín D; Haldford T; Mustermann L; Ocampo C. 2010. Environmental risk factors for the incidence of American Cutaneous Leishmaniasis in a Sub-Andean zone of Colombia (Chaparral, Tolima). Am J Trop Med Hyg. 82(2):243-250 

Travi BL; Osorio EY; Saldarriaga AO;  Cadena H;  Tabares C; Peniche A; Shuko Lee; Melby PC. 2009. Clinical, parasitological and immunological evolution in dogs experimentally infected with sand fly-derived Leishmania chagasi promastigotes. Am J Trop Med Hyg. 2009.81(6):994-1003  

Figueroa R; Lozano LE; Romero IC; Cardona MT; Prager M; Tellez J; Saravia NG. 2009. Detection of Leishmania in unaffected mucosal tissues of patients with American cutaneous leishmaniasis.  J Infect Dis. 200(4):638-646  

Zea D; Prager M; Figueroa R; Miranda MC. 2009. Complicación mucosa de la Leishmaniasis cutánea. Biomédica. 29(1):9 – 11  

Rodríguez-Barraquer I; Góngora R; Prager M; Pacheco R; Navas A; Ferro C; Miranda M C; Saravia NG. 2008. Etiologic agent of the epidemic of cutaneous Leishmaniasis in Tolima, Colombia. Am J Trop Med Hyg. 78(2):276-282.

Cortázar T; Coombs GH; Walker J. 2007. Leishmania panamensis: Comparative inhibition of nuclear DNA topoisomerase II enzymes from promastigotes and human macrophages reveals anti-parasite selectivity of fluoroquinolones, flavonoids and pentamidine. Exp Parasitol. 116(4):475-482

Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo R, Saravia NG. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis. 2007 Feb 15;195 (4):602-8.

Vergel C, Palacios R, Cadena H, Posso CJ, Valderrama L, Perez M,  Walker J, Travi BL; Saravia NG.  2006. Evidence for Leishmania (Viannia) parasites in the skin and blood of patients before and after treatment.  J Infect Dis. 194(4):503-511 

Rojas R; Valderrama L; Valderrama M; Varona MX; Oullette M; Saravia NG. 2006. Resistance to antimony and treatment failure in human Leishmania (Viannia)  infection. J Infect Dis. 193(10):1375-1383

Saravia NG; Escorcia B; Osorio Y; Valderrama L; Brooks D; Arteaga L; Coombs GH; Mottram J; Travi BL. 2006. Pathogenicity and protective immunogenicity of cysteine proteinase deficient mutants of Leishmania mexicana in non murine models. Vaccine. 24(19):4247--4259 

Jean-Moreno V; Rojas R; Goyeneche D; Coombs GH; Walker J. 2006. Leishmania donovani: Differential activities of classical topoisomerase inhibitors and antileishmanials against parasite and host cells at the level of DNA topoisomerase I and in vitro. Exp Parasitol. 112(1):21-30  

Walker J; Acestor N; Gongora R; Quadroni M; Segura I; Fasel N; Saravia NG. 2006. Comparative protein profiling identifies elongation factor-1b and tryparedoxin peroxidase as factors associated with metastasis in Leishmania guyanensis. Mol and Bioch Parasitol. 145(2):254-264

Saravia NG; Hazbón MH; Osorio Y; Valderrama L; Walker J; Santrich C; Cortázar T; LeBowitz JH; Travi BL. 2005. Protective immunogenicity of the Paraflagellar Rod Protein 2 of Leishmania mexicana.Vaccine. 23(8):984-995

Vergel C; Walker J; Saravia NG. 2005. Amplification of human DNA by primers targeted to Leishmania kDNA and post genome considerations in diagnostic PCR.  Am. J. Trop. Med. Hyg. 72(4):423-429. Descargar en formato PDF

 El Fadili K; Messier N, Leprohon P;  Roy G; Guimond Ch; Trudel N; Saravia NG; Papadopoulou B; Légaré D; Ouellette M. 2005 The role of the ABC transporter MRPA(PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob. Agents Chem. 49(5):1988-1993. Descargar en formato PDF

Murray HW; Berman JD; Davies CD; Saravia NG. 2005. Advances in Leishmaniasis. Lancet. 366: 1561–77

Romero, I.C. Saravia N.G. & Walker J. 2005. Selective action of fluoroquinolones against intracellular amastigotes of  Leishmania (Viannia) panamensis in vitro. J Parasitol. 91(6):1474-1479 

Nancy Gore Saravia. 2004. Can Leishmaniasis still be considered a TDR Category 1 Disease? If moved, What Is required? In Report of the Scientific Working Group on Leishmaniasis. TDR/SWG/04:130. Descargar en formato PDF

Cuervo P;  Cupolillo E; Nehme N; Hernandez V; Saravia NG; Fernandes O. 2004. Leishmania (Viannia): genetic analysis of cutaneous and mucosal strains isolates from the same patient. Experimental Parasitology. 108(1-2):59-66

Travi BL; Tabares CJ; Cadena H. 2006. Leishmania Viannia braziliensis infection in two Colombian dogs: a note on infectivity for sand flies and response to treatment. Biomédica. 26(Supl 1):249-253. Descargar en formato PDF

Guarín N;  Palma G; Primes C; Valderrama L; Tovar R; Saravia NG. 2006. Comparative immunohistological analysis of the Montenegro skin test reaction in asymptomatic infection and in acute and chronic cutaneous leishmaniasis.  Biomedica. 26(Supl 1):38-46. Descargar en formato PDF

Bonilla-Escobar DL. 2005. Respuesta inmune a la Leishmaniasis: Algo más que linfocitos T. Piel. 20(8):385 – 395. Descargar en formato PDF  

Henao HH; Osorio Y; Saravia NG; Gómez A; Travi BL. 2004. Eficacia y toxicidad de los antimoniales pentavalentes (glucantime® y pentostam®) en un modelo animal de leishmaniasis cutánea americana: aplicación de la luminometría. Biomédica. 24(4):393 – 402. Descargar en formato PDF

Cortázar TM. & Walker J. 2004. Manipulación genética y el estudio del parásito Leishmania.   Biomédica. 24(4): 438 – 455 (Biomédica 2004_24_4_438-455 Tania Cortázar)